 AIM ImmunoTech Inc NYSEAMERICAN:AIM announced it has signed a contract to sponsor a Phase 2a Human Challenge Trial HCT to test the companys Ampligen drug as a potential intranasal antiviral therapy to treat Rhinovirus hRV common cold virus and Influenza. The company said a successful Phase 2a study could establish Ampligen as a potential prophylaxis against future viral variants and future novel respiratory viruses for which there are no current therapies, as well as known viruses such as SARS-CoV-2, which causes coronavirus COVID-19. 